Drug Trial Radar · NCT02196506
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Last checked: Nov 20, 2026Latest source record: Aug 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
837
Actual
Start
Jul 2014
Primary completion
Apr 2016
Study completion May 2016
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- Collaborators
- H. Lundbeck A/S
- First posted
- Jul 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress
Conditions
- Depressive Disorder
- Depression
- Depressive Disorder, Major
- Mood Disorders
- Mental Disorders
Interventions
Placebo + ADTDrug
Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
Brexpiprazole +ADTDrug
Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the Montgomery-Asberg DepressionTime frame: From baseline (end of Phase A [Week 8]) to week 14
Locations
47 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Beverly Hills, California
Site not named
Denver, Colorado
Site not named
Hialeah, Florida
Site not named
Orlando, Florida
Site not named
Alpharetta, Georgia
Site not named
Smyrna, Georgia
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Rochester Hills, Michigan
Site not named
Cherry Hill, New Jersey
Site not named
Jamaica, New York
Site not named
New York, New York
Site not named
Staten Island, New York
Site not named
Raleigh, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Edmond, Oklahoma
Site not named
Portland, Oregon
Site not named
Salem, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Lincoln, Rhode Island
Site not named
Columbia, South Carolina
Site not named
Memphis, Tennessee
Site not named
Wichita Falls, Texas
Site not named
Murray, Utah
Site not named
Woodstock, Vermont
Site not named
Charlottesville, Virginia
Site not named
Richmond, Virginia
Site not named
Seattle, Washington
Site not named
Spokane, Washington
Site not named
Achim, Germany
Site not named
Berlin, Germany
Site not named
Düsseldorf, Germany
Site not named
Frankfurt, Germany
Site not named
Freiburg im Breisgau, Germany
Site not named
Oranienburg, Germany
Site not named
Stralsund, Germany
Site not named
Würzburg, Germany
Site not named
Budapest, Hungary
Site not named
Győr, Hungary
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.